Adelaide A. Hebert, MD

This publication was developed independently by MJH Life Sciences Global Medical Affairs. Support for the thought leaders meeting and the publication was provided by Arcutis Biotherapeutics, Inc; The Bristol Myers Squibb Company; Janssen Global Services, LLC; and UCB, Inc.

Dermatologists end their discussion on seborrheic dermatitis (SD), highlighting key takeaways for patients and clinicians on managing this condition.

Experts discuss the profound impact of seborrheic dermatitis on a patients' well-being, examining the common misconceptions, diagnostic delays, and societal judgments that hinder effective management and necessitate enhanced clinical outreach and patient education.

Dermatologists discuss the realm of emerging therapies for seborrheic dermatitis (SD), emphasizing the importance of both breakthrough and failed trials, while highlighting the need for scientific rigor and patient-reported outcomes.

Experts reflect on the transformative shift in seborrheic dermatitis treatment, offering effective and time-efficient solutions to identify the disease and educate patients about it.

Dermatologists discuss clinical considerations when treating seborrheic dermatitis across diverse skin types, addressing common symptoms, concerns, and overall efficacy.

Experts explore the challenges of multi-product topical treatment algorithms for seborrheic dermatitis (SD) and the value of once-a-day solutions in fostering adherence, improved quality of life, and overall better outcomes.

Dermatologists discuss the safety and efficacy of roflumilast for seborrheic dermatitis (SD), highlighting its tolerability across backgrounds and age groups, safety in pediatric care, and the unmet need it fulfills.

Dermatologists discuss a groundbreaking agent, roflumilast, filling a void in seborrheic dermatitis (SD) treatment. These experts highlight patient-reported response to this novel treatment and their own experiences in clinical trials with this drug.

Dermatologists discuss diverse patient presentations and effective treatments for seborrheic dermatitis (SD), addressing over-the-counter product challenges, immune signatures, and treatment nuances in pediatric care.

Experts shed light on the challenges of seborrheic dermatitis treatment, emphasizing the historical lack of treatment options and importance of patient education.

Dermatologists discuss the profound impact of seborrheic dermatitis on an individual’s quality of life, discussing self-reported effects on self-esteem, social interactions, and career trajectories.

Dermatologists discuss differentiating seborrheic dermatitis from conditions like psoriasis, eczema, and lupus, highlighting similarities and differences with other skin conditions.

Dermatologists introduce this series providing and overview of seborrheic dermatitis (SD), highlighting common causes, contributing factors, and the various ways it may present in different patient populations.

Experts in dermatology share advice on helping fellow physicians stay apprised of the advances in AD and treat their patients more effectively.

Expert dermatologists consider ongoing trials and emerging treatment options for the management of AD.

Experts in dermatology share general guidance for use of topicals, switching from topical to systemic treatment, and when combination therapy is an option for patients with atopic dermatitis.

Omar Noor, MD, and Adelaide A. Hebert, MD, discuss monitoring requirements for various classes of treatments in atopic dermatitis, including topical vs systemic.

Peter A. Lio, MD, reviews treatment options for patients with moderate AD.

Matthew Zirwas, MD, shares goals of therapy for a patient with AD.

Expert dermatologists address the clinical implications of boxed warnings of topical treatments in AD.

Matthew Zirwas, MD, and Omar Noor, MD, comment on their own experience of time to response with topical and systemic treatments of AD.

Peter A. Lio, MD, discusses the durability of topical treatments in AD, including steroids, calcineurin inhibitors, and JAK inhibitors.

Experts discuss long-term efficacy data for topical medications for the treatment of AD.

Matthew Zirwas, MD, and Omar Noor, MD, review a patient scenario where AD disease activity is limited but in difficult to treat locations.

Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.

Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.

Expert dermatologists discuss the durability of long-term use of topical steroids for treatment of atopic dermatitis.

Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.

Experts in dermatology discuss which disease characteristics play the biggest role in influencing treatment choice or change of treatment from the perspective of a patient with atopic dermatitis.